Holen Sie sich die Stockscreener-App
21.27
4.01%
0.82
Schlusskurs vom Vortag:
$20.45
Offen:
$20.8
24-Stunden-Volumen:
898.76K
Relative Volume:
0.80
Marktkapitalisierung:
$3.61B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-323.01M
KGV:
-9.5811
EPS:
-2.22
Netto-Cashflow:
$-272.30M
1W Leistung:
+4.62%
1M Leistung:
-9.83%
6M Leistung:
-34.47%
1J Leistung:
-41.73%
1-Tages-Spanne:
$20.80
$21.66
1-Wochen-Bereich:
$20.40
$21.66
52-Wochen-Spanne:
$19.07
$39.55
Immunovant Inc Stock (IMVT) Company Profile
Firmenname
Immunovant Inc
Sektor
Branche
Telefon
917-580-3099
Adresse
320 WEST 37TH STREET, NEW YORK, NY
Vergleichen Sie IMVT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
21.27 | 3.61B | 0 | -323.01M | -272.30M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-03 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-10-09 | Bestätigt | Oppenheimer | Outperform |
| 2024-03-28 | Eingeleitet | Oppenheimer | Outperform |
| 2024-03-13 | Eingeleitet | Goldman | Buy |
| 2024-02-20 | Eingeleitet | JP Morgan | Overweight |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-13 | Hochstufung | UBS | Neutral → Buy |
| 2023-09-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | Eingeleitet | BofA Securities | Buy |
| 2023-04-25 | Eingeleitet | Citigroup | Buy |
| 2023-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2023-03-30 | Eingeleitet | Stifel | Buy |
| 2023-02-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-01-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | Herabstufung | UBS | Buy → Neutral |
| 2021-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-08-03 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-06-01 | Herabstufung | Stifel | Buy → Hold |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-10-12 | Eingeleitet | Guggenheim | Buy |
| 2020-10-08 | Eingeleitet | Stifel | Buy |
| 2020-10-02 | Eingeleitet | Credit Suisse | Outperform |
| 2020-08-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-07-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-24 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Immunovant Inc Aktie (IMVT) Neueste Nachrichten
Immunovant CEO Peter Salzmann sells $322,057 in stock to cover tax obligations - Investing.com Canada
Immunovant, Inc. (IMVT): Is It The Most Oversold Healthcare Stock to Buy Now? - Insider Monkey
Immunovant’s chief medical officer Macias sells $42,867 in stock By Investing.com - Investing.com Nigeria
Immunovant's chief medical officer Macias sells $42,867 in stock - Investing.com India
Immunovant Executives Sell Shares to Cover Tax Obligations - TradingView
12 Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
Immunovant, Inc. (IMVT): Among Stocks Insiders Spent The Most Money On Recently - MSN
Biotech Kingpin: Why Insiders Are Betting Big on Immunovant - Reporteros del Sur -
ABC Arbitrage SA Invests $734,000 in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Banque Pictet & Cie SA Sells 13,440 Shares of Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
(IMVT) Investment Analysis and Advice - Stock Traders Daily
Immunovant Inc [IMVT] Shares Rise 3.33 % on Thursday - Knox Daily
Guggenheim cuts Immunovant stock target to $44, maintains Buy - MSN
Immunovant (NASDAQ:IMVT) Given New $44.00 Price Target at Guggenheim - MarketBeat
Immunovant's Key Batoclimab Trial Catalysts Expected By MarchCan The Stock Bounce Back? - RTTNews
Immunovant FY2025 EPS Estimate Raised by Leerink Partnrs - MarketBeat
Immunovant stock hits 52-week low at $19.08 amid challenges By Investing.com - Investing.com Canada
Immunovant stock hits 52-week low at $19.08 amid challenges - Investing.com
Immunovant (IMVT) Loses -15.47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Nasdaq
Immunovant (NASDAQ:IMVT) Hits New 12-Month Low After Earnings Miss - MarketBeat
Immunovant, Inc. (NASDAQ:IMVT) Shares Acquired by abrdn plc - MarketBeat
Guggenheim cuts Immunovant stock target to $44, maintains Buy By Investing.com - Investing.com Australia
IMVT Q3 Loss Wider Than Expected, Stock Down, Pipeline in Focus - MSN
Immunovant (NASDAQ:IMVT) Price Target Cut to $44.00 by Analysts at Guggenheim - Defense World
Immunovant (NASDAQ:IMVT) Reaches New 12-Month Low on Disappointing Earnings - Defense World
Immunovant’s (IMVT) Buy Rating Reiterated at HC Wainwright - Defense World
Immunovant, Inc. (NASDAQ:IMVT) Receives $47.00 Consensus PT from Analysts - Defense World
Oppenheimer Adjusts Price Target on Immunovant to $54 From $53, Keeps Outperform Rating - Marketscreener.com
Immunovant (NASDAQ:IMVT) Issues Quarterly Earnings Results - MarketBeat
Immunovant, Inc. (NASDAQ:IMVT) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Immunovant (NASDAQ:IMVT) Shares Down 5% Following Weak Earnings - MarketBeat
HC Wainwright Reaffirms Buy Rating for Immunovant (NASDAQ:IMVT) - MarketBeat
Immunovant Inc [NASDAQ: IMVT] Sees Decrease in Stock Value - Knox Daily
IMVT’s Market Whiplash: -17.80% YTD Decline, -17.34% Plunge in 30 Days - The InvestChronicle
Immunovant (NASDAQ:IMVT) Stock Price Down 5% on Disappointing Earnings - Defense World
Immunovant Reports Progress Amid Increased R&D Costs - TipRanks
Immunovant (NASDAQ:IMVT) Sets New 1-Year LowHere's What Happened - MarketBeat
Immunovant's Fiscal Q3 Loss Widens -February 06, 2025 at 07:40 am EST - Marketscreener.com
Immunovant Inc. (IMVT) reports earnings - Quartz
Finanzdaten der Immunovant Inc-Aktie (IMVT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Immunovant Inc-Aktie (IMVT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Barnett Eva Renee | Chief Financial Officer |
Feb 19 '25 |
Sale |
20.86 |
2,814 |
58,700 |
321,952 |
| Salzmann Peter | Chief Executive Officer |
Feb 19 '25 |
Sale |
20.86 |
15,439 |
322,058 |
948,786 |
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):